

CATABASIS PHARMACEUTICALS, INC.
100 HIGH STREET, 28TH FLOOR
Boston, MA 02110

April 14, 2021

Via EDGAR

Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549

Re: Catabasis Pharmaceuticals, Inc.
Registration Statement on Form S-3
File No. 333-254174
Request for Acceleration

Ladies and Gentlemen:

Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Catabasis Pharmaceuticals, Inc. (the “**Registrant**”) hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333-254174) (the “**Registration Statement**”), so that it may become effective at 4:00 p.m. Eastern time on April 16, 2021, or as soon thereafter as practicable.

[The remainder of this page is intentionally left blank.]

Very truly yours,

Catabasis Pharmaceuticals, Inc.

By: /s/ Ben Harshbarger

Name: Ben Harshbarger

Title: Senior Vice President, General Counsel

[Signature Page to Request for Acceleration]
